Rosiglitazone is a thiazolidinedione indicated as an adjunct to diet and exercise to maintain glycemic control in type 2 diabetes. Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs.
- Mechanism
- Curator reviewed
Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.
- Primary indication
- Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Curator reviewed · 1 structured indication
- Formula / weight
- C18H19N3O3S · 357.427 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1999
- Code names
- BRL-49653 · TDZ-01
- Brand names
Resolves to
YASAKCUCGLMORW-UHFFFAOYSA-NSMILESCN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1What you can answer from here — as of September 23, 2026
Which drugs share a target with Rosiglitazone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account